Nanomedicine in Cancer Treatment: Harnessing Nanotechnology for Targeted Drug Delivery and Advanced Imaging Techniques

Nanomedicine has transformed cancer treatment by utilizing nanotechnology to create more precise, targeted, and less toxic therapies. Traditional methods like chemotherapy and radiation often lack specificity, causing side effects and limiting effectiveness. Nanoparticles, sized between 1 and 100 nanometres, enable targeted drug delivery, minimizing damage to healthy tissues. Through the improved Permeability along with Retention (EPR) effect, nanoparticles accumulate in tumours due to leaking vasculature. Active targeting, using ligands like antibodies, enhances precision by interacting with specific cancer receptors, such as HER2 in breast cancer. Doxil is a liposomal preparation of doxorubicin that improves progression-free survival in ovarian cancer patients by reducing cardiotoxicity. Nanoparticles also enhance cancer imaging, improving the resolution of techniques like MRI, CT, and PET. Gold nanoparticles and iron oxide nanoparticles act as contrast agents, aiding early tumor detection. Furthermore, Theranostic nanoparticles integrate therapeutic and diagnostic functions, facilitating real-time assessment of treatment efficacy for enhanced tailored care. Despite its potential, Nanomedicine faces challenges like toxicity, immune clearance, and scalability. Nanoparticles may be identified and eliminated via the reticuloendothelial system (RES), reducing efficacy. However, solutions like PEGylation and biodegradable nanoparticles are addressing these barriers. The global Nanomedicine marketplace, valued at $150 billion in 2021, is anticipated to expand at a compound annual growth rate (CAGR) of 11.9% complete 2030, underscoring the expanding role of nanotechnology in cancer treatment.